Osteoporosis: non-hormonal treatment

References

• Bone H G, Hosking D, Devogelaer J P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189–1199
   PubMed Web of Science ®Google Scholar
• Black D M, Schwartz A V, Ensrud K E, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927–2938
   PubMed Web of Science ®Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004; 20: 433–439
   PubMed Web of Science ®Google Scholar
• Chesnut I C, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241–1249
   PubMed Web of Science ®Google Scholar
• Reginster J Y, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the Mobile Study. Ann Rheum Dis 2006; 65: 654–661
   PubMed Web of Science ®Google Scholar
• Delmas P D, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration Study. Arthritis Rheum 2006; 54: 1838–1846
   PubMed Web of Science ®Google Scholar
• Solomon D H, Brookhart M A, Gandhi T K, et al. Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. Am J Med 2004; 117: 919–924
   PubMed Web of Science ®Google Scholar
• Rosen C J, Hochberg M C, Bonnick S L, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20: 141–151
   PubMed Web of Science ®Google Scholar
• Silverman S L, Watts N B, Delmas P D, Lange J L, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The Risedronate And Alendronate (REAL) cohort study. Osteoporos Int 2007; 18: 25–34
   PubMed Web of Science ®Google Scholar
• Boonen S, McClung M R, Eastell R, El-Hajj Fuleihan G, Barton I P, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52: 1832–1839
   PubMed Web of Science ®Google Scholar
• Boonen S, Laan R F, Barton I P, Watts N B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005; 16: 1291–1298
   PubMed Web of Science ®Google Scholar
• Delmas P D, Genant H K, Crans G G, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522–532
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari H A, Dawson-Hughes B, Willett W C, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004; 291: 1999–2006
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari H A, Willett W C, Wong J B, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293: 2257–2264
   PubMed Web of Science ®Google Scholar
• Grant A M, Avenell A, Campbell M K, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or Vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365: 1621–1628
   PubMed Web of Science ®Google Scholar
• Jackson R D, Lacroix A Z, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669–683
   PubMed Web of Science ®Google Scholar
• Boonen S, Vanderschueren A, Haetjens P, Lips P. Evidence for hip fracture risk reduction with calcium and vitamin D from a comparative meta-analysis of randomized controlled trials. J Bone Miner Res 2006; 21: S60
   Web of Science ®Google Scholar
• Silverman S L, Mathisen A, Gallwitz W. Effect of parathyroid hormone (1–84) in reducing new vertebral fractures regardless of baseline vertebral fracture status in patients with a wide range of clinical risk factors. J Bone Miner Res 2006; 21: S173
   Web of Science ®Google Scholar
• Black D M, Bilezikian J P, Ensrud K E, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 2005; 353: 555–565
   PubMed Web of Science ®Google Scholar
• Meunier P J, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459–468
   PubMed Web of Science ®Google Scholar
• Reginster J Y, Seeman E, De Vernejoul M C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment Of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005; 90: 2816–2822
   PubMed Web of Science ®Google Scholar
• Reginster J Y, Roux C, Compston J, Ortolani S. Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti-fracture efficacy over 5 years in post-menopausal osteoporotic women. Osteoporos Int 2006; 17: S14
   Google Scholar
• McClung M R, Lewiecki E M, Cohen S B, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821–831
   PubMed Web of Science ®Google Scholar